FAVULOUS: Exercise Program for Arteriovenous Fistula Maturation

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Recruiting
CT.gov ID
NCT04034433
Collaborator
(none)
40
1
2
37
1.1

Study Details

Study Description

Brief Summary

Arteriovenous fistula (AVF) is the recommended vascular access for chronic hemodialysis, as it is associated with less mortality and better patency than arteriovenous graft (AVG) or central venous catheter (CVC).

Unfortunately, AVF suffers from a high failure rate, due, in part, to poor venous diameter.

The aim of this study is to investigate whether a perioperative handgrip training can improve the diameter of AVF in patients with chronic kidney disease (CKD) (stage IV-V).

Condition or Disease Intervention/Treatment Phase
  • Procedure: Handgrip exercise program
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Benefits of a Perioperative Exercise Program on Maturation of Dialysis Arteriovenous Fistulas
Actual Study Start Date :
Oct 4, 2019
Anticipated Primary Completion Date :
Nov 4, 2022
Anticipated Study Completion Date :
Nov 4, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exercise

Procedure: Handgrip exercise program
Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.

No Intervention: Control

Outcome Measures

Primary Outcome Measures

  1. Arteriovenous Fistula (AVF diameter) [at 6 weeks (after surgery)]

    Arteriovenous Fistula diameter will be measured by Doppler ultrasound

Secondary Outcome Measures

  1. Echographic maturation rate [at 6 weeks (after surgery)]

    Maturation rate of Arteriovenous Fistula (AVF) by echography defined as blood flow>600milliLiters/minute (mL/min), diameter>6millimeters (mm) and depth <6mm

  2. Clinical maturation rate [at 6 weeks (after surgery)]

    Arteriovenous Fistula (AVF) measured by a vein easily palpable, relatively straight, with a uniform sensation of quivering and more than 10centimeters (cm) long.

  3. Arteriovenous Fistula (AVF) localization (arm or forearm) [at 6 weeks (after surgery)]

    After the patient's examination, the vascular surgeon will choose the future AVF localization

  4. Arteriovenous Fistula (AVF) interventions [up to 6 weeks]

    Necessity of performing an intervention (such as angioplasty or thrombolysis or thrombectomy or superficialization) on the Arteriovenous Fistula (AVF)

  5. Emergency hemodialysis on Central Venous Catheter (CVC) [up to 6 weeks]

    Necessity of patients on CVC to undergo emergency hemodialysis

  6. Emergency hemodialysis on Arteriovenous Graft (AVG) [up to 6 weeks]

    Necessity of patients on AVG to undergo emergency hemodialysis

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients older than 18 years

  • with chronic kidney disease (Estimated Glomerular Filtration Rate (eGFR) <30 milliLiter/minute (mL/min))

  • with follow-up at the University Hospital of Lyon Sud

  • who choose hemodialysis as renal replacement therapy

Exclusion Criteria:
  • contraindication for arteriovenous fistula (AVF) surgery

  • refusing AVF creation

  • prior vascular access

  • antecedent of IV substance abuse

  • active cancer

  • inability to perform handgrip exercise

  • physical or mental disability limiting follow-up possibility

  • inclusion in an other interventional study

  • no social welfare

Contacts and Locations

Locations

Site City State Country Postal Code
1 Service de néphrologie, dialyse et nutrition rénale - Centre Hospitalier Lyon Sud Pierre-Bénite France 69310

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

  • Principal Investigator: Abbas DEEB, PhD, Hospices Civils de Lyon

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT04034433
Other Study ID Numbers:
  • 69HCL19_0215
  • ID-RCB
First Posted:
Jul 26, 2019
Last Update Posted:
Jun 29, 2021
Last Verified:
Jun 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospices Civils de Lyon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 29, 2021